MLMC Therapeutics ApS: Financial statements 2025
CVR: 41277688
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
MLMC Therapeutics ApS (CVR 41277688) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -30,768 and a net result of DKK -144,214 compared with DKK -134,525 the year before. Equity in the 2025 report amounted to DKK -483,287.
- Gross Profit
- DKK -30,768
- Profit/Loss
- DKK -144,214
- Equity
- DKK -483,287
- Total Assets
- DKK 88,628
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -31 t. | -144 t. | -483 t. | - |
| 2024 | - | -27 t. | -135 t. | -339 t. | - |
| 2023 | - | -26 t. | -123 t. | -205 t. | - |
| 2022 | - | -30 t. | -90 t. | -82 t. | - |
| 2021 | - | -20 t. | -54 t. | 8 t. | 0 |
Official annual report
How creditworthy is MLMC Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
MLMC Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -26,638, and the net result was DKK -134,525.
About MLMC Therapeutics ApS
MLMC Therapeutics ApS is a Danish company of the type Anpartsselskab based in Kastrup, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Michael Henrik Stadi. The board consists of Martin Kiener (chair), Hanne Damgaard Jensen and Peter Gudmund Nielsen. The company's owners include Ritika Singh Petersen, Sriram Thoppe Rajendran and FOMT HOLDING ApS. According to the 2021 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -30,768 and a net result of DKK -144,214 compared with DKK -134,525 the year before. Equity in the 2025 report amounted to DKK -483,287.